Get started
SPDR SERIES TRUST SPDR S&P BIOTECH ETFSPDR SERIES TRUST SPDR S&P BIOTECH ETFSPDR SERIES TRUST SPDR S&P BIOTECH ETF

SPDR SERIES TRUST SPDR S&P BIOTECH ETF

No trades
See on Supercharts
Overview Analysis News
Ideas
Discussions Technicals Seasonals

XBI trade ideas

$XBI - Fundamentally Undervalued, Strong Bounce Off Of SupportI posted the wrong chart when doing my analysis on this ticker last time, so I'm here to update my error! This is a very interesting sector to keep an eye on after it's gotten relentlessly hammered for the past six months. There are now over 100 biotech stocks selling below cash, meaning these companies literally have more cash on their balance sheet than their entire market cap! Furthermore, there are 300 additional biotech stocks selling at 1/2 cash (50% of their balance sheet is at least half of their current market cap). There are an insane amount of bargains within this sector, and the entire sector is poised to make a reversal after a strong bounce off of support, and bullish engulfing candle on the daily. I wouldn't be surprised to see this entire batch of stocks start to perform very well over the following months. A trip back to the 130s is almost inevitable.
AMEX:XBILong
by FluxTrades
3
$XBI - Fundamentally Undervalued, Strong Bounce Off Of SupportThis is a very interesting sector to keep an eye on after it's gotten relentlessly hammered for the past six months. There are now over 100 biotech stocks selling below cash, meaning these companies literally have more cash on their balance sheet than their entire market cap! Furthermore, there are 300 additional biotech stocks selling at 1/2 cash (50% of their balance sheet is at least half of their current market cap). There are an insane amount of bargains within this sector, and the entire sector is poised to make a reversal after a strong bounce off of support, and bullish engulfing candle on the daily. I wouldn't be surprised to see this entire batch of stocks start to perform very well over the following months. A trip back to the 130s is almost inevitable.
AMEX:XBILong
by FluxTrades
Biotech primed for a move higher?This one is almost pure intuition. We're in pharmaceuticals earnings season now. Seagen reports after market today. A bunch of other large holdings of XBI report on November 3-4, and a bunch more on November 8. Bonds and tech stocks have made a breakout move upward, and small caps look primed. (XBI is full of small and micro caps.) XBI has had a long consolidation here, and I really like the price action on it today. A lot of other sector funds have had mid-day pullbacks, but XBI has maintained its steady upward slope. It has poked above the 20-day EMA. My guess is that this will be green again tomorrow, so I've rolled the dice on a call expiring October 29. I'm also looking for continuation the next two weeks, with a first target of about 131.75.
AMEX:XBILong
by ChristopherCarrollSmith
17
The biotech sector may be a big winner into the year’s endThe $XBI has been one of the worst performing ETFs this year as the biotech sector faced important headwinds coming from Washington. A cap on prices has been since dropped, which is extremely beneficial for the long term. In addition, from a historical perspective, November and December are this ETF’s strongest months. The candidates for the Ash conference of biotechs will be announced this week which may prove to be yet another positive catalyst. We are long some $XBI calls for January and continue to hold our small bio spec play, $MBIO.
AMEX:XBILong
by Eclubtrading
XBI (SPDR S&P Biotech ETF) is Bull to at least ~134.37Prediction: XBI (SPDR S&P Biotech ETF) is Bull to at least ~134.37 (Resistance line) Reason: The chart is filled with Bull Harmonic Patterns. From the "Gartley" pattern (recent), to the larger "Butterfly" pattern which gives the overall reversal, to the in between "Shark" Bull Pattern. Every timeline shows new bull patterns. The Volume Flow is increasing, and the momentum is strong. Currently, it is consolidating but the bull pressure is too strong. It will pass the next resistance of 130.40 and then reach the resistance of 134.40. (Momentum will probably continue afterwards).
AMEX:XBILong
by KevInnerTrading
XBI will complete upwards 26 period than go up 1 or 2 cyclesXBI (Small Cap Biotech Index) is due for 2 or 3 upwards movements (includes current wave). XBI moves in cycles of 2 or 3 (or 4 when it became overextended) and in between we have a 1, 1 pattern (it takes a break) where it goes up 1 sideways / 1 down, or 1 up / 1 down. I predict it will complete the upwards 26 period and then go upwards for 1 or 2 more 26 candle periods (daily timeframe). The pattern doesn't say if it is going to move for 2 or 3 but it shows that it can be one or the other. In addition, I factor the current bullish signs for XBI which helps to support this theory. Note: The stock GH is included but hidden in order to allow me to show the higher pattern. It just a way to scale up the chart.
AMEX:XBILong
by KevInnerTrading
Double Bottom RectangleXBI formed a double bottom. The bulls made a stand at this level. Appears to be in a rectangle which is a neutral pattern until a trendline is broken with a trend in that direction. The top trendline of a rectangle is resistance. The bottom is support. It is a horizontal trading channel and price can bounce back and forth until a trendline is broken. No recommendation. SPDR Series Trust - SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI"). Benchmark: S&P Biotechnology Select Industry TR USD. Top 10 Holdings Intellia Therapeutics Inc 1.15% Moderna Inc 1.12% Cytokinetics Inc 0.98% Celldex Therapeutics Inc 0.91% Translate Bio Inc 0.90% Arcus Biosciences Inc 0.87% Veracyte Inc 0.85% ChemoCentryx Inc 0.84% Biohaven Pharmaceutical Holding Co Ltd 0.83% Kymera Therapeutics Inc Ordinary Shares
AMEX:XBI
by lauralea